In Clinical Trials, Treatment Proved More Effective Than Other Therapies Evaluated
Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.
โGiven the challenges many patients experience in achieving their target blood sugar goals, todayโs approval of Mounjaro is an important advance in the treatment of type 2 diabetes,โ said Patrick Archdeacon, M.D., associate director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAโs Center for Drug Evaluation and Research.
Type 2 diabetes, the most common form of diabetes, is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose (sugar) in the blood. More than 30 million Americans have type 2 diabetes. Despite the availability of many medications to treat diabetes, many patients do not achieve the recommended blood sugar goals.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control. Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control. Mounjaro is administered by injection under the skin once weekly, with the dose adjusted as tolerated to meet blood sugar goals.
Three different doses of Mounjaro (5 milligrams, 10 milligrams and 15 milligrams) were evaluated in five clinical trials as either a stand-alone therapy or as an add-on to other diabetes medicines. The efficacy of Mounjaro was compared to placebo, a GLP-1 receptor agonist (semaglutide) and two long-acting insulin analogs.
On average, patients randomized to receive the maximum recommended dose of Mounjaro (15 milligrams) had lowering of their hemoglobin A1c (HbA1c) level (a measure of blood sugar control) by 1.6% more than placebo when used as stand-alone therapy, and 1.5% more than placebo when used in combination with a long-acting insulin. In trials comparing Mounjaro to other diabetes medications, patients who received the maximum recommended dose of Mounjaro had lowering of their HbA1c by 0.5% more than semaglutide, 0.9% more than insulin degludec and 1.0% more than insulin glargine.
Obesity was common among study participants, with an average body mass index of 32 to 34 kilograms/height in meters squared reported at the time of enrollment. Among patients randomized to the maximum recommended dose, the average weight loss with Mounjaro was 15 pounds more than placebo when neither were used with insulin and 23 pounds more than placebo when both were used with insulin. The average weight loss with the maximum recommended dose of Mounjaro was 12 pounds more than semaglutide, 29 pounds more than insulin degludec and 27 pounds more than insulin glargine. Those patients receiving insulin without Mounjaro tended to gain weight during the study.
Mounjaro can cause nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort and abdominal pain.
Mounjaro causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes such tumors, including medullary thyroid cancer, in humans. Mounjaro should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2.
Mounjaro has not been studied in patients with a history of pancreas inflammation (pancreatitis), and it is not indicated for use in patients with type 1 diabetes.
Mounjaro received priority review designation for this indication. A priority review designation directs overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions.
The FDA granted the approval of Mounjaro to Eli Lilly and Co.
Related Information
- Many older adults lack clear eyesight, even with glasses
Vision impairment disproportionately impacts older adults Newswise โ New research shows that 28% of people over the age of 71 have a visual โฆ Many older adults lack clear eyesight, even with glasses TNCRod Washington:ย ย Rod is a blogger, writer, filmmaker, photographer, daydreamer who likes to cook. Rod produces and directs the web series, CUPIC: Diaryโฆ Read more: Many older adults lack clear eyesight, even with glasses - Stork Club Announces the First Gender-Inclusive Reproductive Hormone Therapy Coverage to Address Growing Demand
Leading family-building management solution is the only employer-sponsored program to close gaps in hormone therapy care for all genders: menopause, hormonal health optimization and gender-affirming care - OBSERVING WORLD AIDS DAY
WORLD AIDS DAY Every year, World AIDS Day is held on December 1st to raise awareness of the AIDS pandemic and to mourn those who have died from the disease. According to the most recent statistics, nearly 38 million people around the world are living with HIV. The Human Immunodeficiency Virus is the virus thatโฆ Read more: OBSERVING WORLD AIDS DAY - The undying holiday-suicide myth
Some news media stories still inaccurately link suicide with the holiday season Newswise โ PHILADELPHIA โ The holiday-suicide myth, the false claim that the suicide rate rises during the year-end holiday season, persisted in some news coverage through the 2021-22 holidays, according to U.S. media data collected and analyzed by theย Annenberg Public Policy Centerย (APPC) ofโฆ Read more: The undying holiday-suicide myth - American Indian Teens Who Anticipate Future Affiliation with their Native Culture Experience Fewer Negative Consequences of Drinking
Newswise โ American Indian (AI) adolescents who expect to relate strongly to their racial culture in the future are less likely than their peers to experience negative alcohol outcomes – like fighting with friends, being arrested, and memory gaps – even if they do not relate strongly to their culture now, a new study suggests.โฆ Read more: American Indian Teens Who Anticipate Future Affiliation with their Native Culture Experience Fewer Negative Consequences of Drinking
Rod Washington:ย ย Rod is a blogger, writer, filmmaker, photographer, daydreamer who likes to cook. Rod produces and directs the web series, CUPIC: Diary of an Investigator. He also produces news and documentary video projects. Check out his podcast StoriesThisMoment atย https://m3e.d71.myftpupload.com/stm-tncn-podcasts/
